Autoimmune hepatitis is an independent risk factor for allograft loss and morbidity after liver transplantation: evidence from the Swiss Transplant Cohort Study
Year: 2026
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Liver transplantation is the only curative option for end-stage autoimmune hepatitis (AIH). Although overall outcomes are favourable, previous studies suggest an increased risk of allograft loss and mortality in this population. We assessed post-liver transplantation outcomes in AIH recipients using data from the nationwide multicentre Swiss Transplant Cohort Study (STCS). METHODS: We included all adult patients undergoing a first liver transplantation between May 2008 and December 2020. Indications were categorised as AIH, alcohol-related liver disease, viral liver disease, primary biliary cholangitis, primary sclerosing cholangitis, metabolic dysfunction-associated liver disease or other/mixed aetiologies. Survival analyses and multivariable competing risk Cox models were applied. Clinical Registration number (CER-VD): 2021-01982. RESULTS: Among 880 liver transplantation recipients, 23 (2.6%) underwent liver transplantation for AIH. The 1-, 5- and 10-year post-liver transplantation survival rates in the AIH group were 87.0%, 76.5% and 76.5%, respectively – comparable to other indications. Allograft failure occurred in 34.8% of AIH recipients, significantly more often than in alcohol-related liver disease (8.3%, p <0.001), viral liver disease (13.5%, p = 0.003), primary sclerosing cholangitis (12.2%, p = 0.029) and metabolic dysfunction-associated liver disease (8.2%, p = 0.005). On multivariable analysis, AIH remained independently associated with increased allograft loss (HR 4.23, 95% CI 1.85–9.64; p = 0.003). Hepatic artery thrombosis occurred in 4/23 AIH patients and caused early allograft failure in all cases. CONCLUSION: Despite comparable long-term survival, AIH recipients had a higher risk of early allograft loss, with vascular complications contributing to several early failures. Although the small AIH sample limited the precision of the estimated effects, these findings suggest the need for tailored pre- and post-transplant surveillance with particular attention to vascular complications.
Source: Swiss Medical Weekly
DOI: 10.57187/5375
Authors: Aurélie Rosat, Benedetta Terziroli Beretta-Piccoli, Linard D. Hoessly, Susanne Stampf, Michael Koller, Nicolas Goossens, Giulia Magini, Philippe Compagnon, Montserrat Fraga, Mirjam Kolev, Nasser Semmo, Annalisa Berzigotti, Vanessa Banz, Beat Müllhaupt, Andreas Kremer, Jose Oberholzer, David Semela, Markus H. Heim, Simon Brunner, Manuel Pascual, Darius Moradpour, Julien Vionnet, the Swiss Transplant Cohort Study
Institutions: Centre Hospitalier Universitaire Vaudois, University of Lausanne, Ente Ospedaliero Cantonale, Università della Svizzera italiana, University Hospital of Basel, University Hospital of Geneva, University of Bern, University Hospital of Bern, University of Zurich, University Hospital Zurich, Kantonsspital St. Gallen, Kantonsspital Graubünden
Language: English
Topic: Liver Diseases and Immunity
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7234620337
